RedHill Biopharma (RDHL) Return on Capital Employed (2014 - 2023)

RedHill Biopharma (RDHL) has 10 years of Return on Capital Employed data on file, last reported at 234.47% in Q2 2023.

• Return on Capital Employed for Q2 2023 came in at 234.47%, up 876690.0% year-over-year; the trailing twelve-month figure through Jun 2023 was 234.47% (up 876690.0% YoY), and the FY2025 annual result was 321.15%, down 70702.0% from the prior year.
• Return on Capital Employed slipped to 234.47% in Q2 2023 per RDHL's latest filing, from 108.68% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 108.68% in Q4 2022 and troughed at 9001.37% in Q2 2022.
• A 5-year average of 982.89% and a median of 58.17% in 2021 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 905954 bps in 2022, then jumped 876690 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 92.79% in 2019, then tumbled by 32 bps to 62.82% in 2020, then slumped by 226 bps to 79.32% in 2021, then soared by 237 bps to 108.68% in 2022, then plunged by 316 bps to 234.47% in 2023.
• Business Quant data shows RDHL's Return on Capital Employed at 234.47% in Q2 2023, 108.68% in Q4 2022, and 9001.37% in Q2 2022.